Limitations, agreements, and source contact

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes · Source last updated 2017-05-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

limitations And Caveats

description

The study was terminated early by the sponsor due to the removal of lintuzumab from the market.

point Of Contact

email

Alison.Walker@osumc.edu

organization

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center

phone

614-293-3196

title

Alison Walker, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice